Another stent for minimally invasive glaucoma surgery. It has been approved by FDA and will be in use in the USA in 2017. It has been found to be effective in refractory glaucoma. Patients have to use less anti-glaucoma medication after the surgery.
The principle of any glaucoma surgery is to create a communication between the anterior chamber and an external space where the aqueous can drain. This reduces the pressure in the eye and the possibility of further damage to optic nerve is minimized.
The traditional surgery for glaucoma is trabeculectomy but newer solutions are being found to make the surgery minimally invasive and more effective.
The stent is a soft, permanent, subconjunctival implant that shunts fluid from the anterior chamber to the subconjunctival space. Approximately 6-mm long and the width of a human hair, the stent comes preloaded in a disposable Xen injector and is implanted through a small, self-sealing corneal incision. The stent’s collagen-derived non-inflammatory gelatin material allows it to conform to the ocular tissue, possibly minimizing many of the issues seen with synthetic materials such as migration, erosion and corneal endothelial damage.